Soluble NKG2D Ligands in the Ovarian Cancer Microenvironment Are Associated with an Adverse Clinical Outcome and Decreased Memory Effector T Cells Independent of NKG2D Downregulation

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2017 Sep 22

PMID 28932639

Citations 21

Authors

Maulik Vyas

Silke Reinartz

Nathalie Hoffmann

Katrin S Reiners

Sonja Lieber

Julia M Jansen

Uwe Wagner

Rolf Muller

Elke Pogge von Strandmann

Affiliations

Soon will be listed here.

Abstract

The immune receptor NKG2D is predominantly expressed on NK cells and T cell subsets and confers anti-tumor activity. According to the current paradigm, immune surveillance is counteracted by soluble ligands shed into the microenvironment, which down-regulate NKG2D receptor expression. Here, we analyzed the clinical significance of the soluble NKG2D ligands sMICA and sULBP2 in the malignancy-associated ascites of ovarian cancer. We show that high levels of sMICA and sULBP2 in ascites were associated with a poor prognosis. Ascites inhibited the activation of normal NK cells, which, in contrast to the prevailing notion, was not associated with decreased NKG2D expression. Of note, an inverse correlation of soluble NKG2D ligands with effector memory T cells and a direct correlation with pro-tumorigenic CD163CD206 macrophages was observed. Thus, the role of soluble NKG2D ligands within the ovarian cancer microenvironment is more complex than anticipated and does not exclusively function via NKG2D downregulation.

Citing Articles

The emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer.

Pounds R, Croft W, Pearce H, Hossain T, Singh K, Balega J Front Immunol. 2025; 15():1477781.

PMID: 39835114 PMC: 11743932. DOI: 10.3389/fimmu.2024.1477781.

Cell type-specific upregulation of NKG2D ligand MICA in response to APTO253.

Alkhayer R, Ponath V, Pogge von Strandmann E Ann Transl Med. 2025; 12(6):113.

PMID: 39817244 PMC: 11729809. DOI: 10.21037/atm-24-20.

Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells.

Obajdin J, Larcombe-Young D, Glover M, Kausar F, Hull C, Flaherty K Cell Rep Med. 2024; 5(11):101827.

PMID: 39566469 PMC: 11604534. DOI: 10.1016/j.xcrm.2024.101827.

Arachidonic acid impairs natural killer cell functions by disrupting signaling pathways driven by activating receptors and reactive oxygen species.

Hammoud M, Meena C, Dietze R, Hoffmann N, Szymanski W, Finkernagel F Cell Commun Signal. 2024; 22(1):555.

PMID: 39563446 PMC: 11575453. DOI: 10.1186/s12964-024-01940-z.

Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.

Chen S, Zhu H, Jounaidi Y Signal Transduct Target Ther. 2024; 9(1):302.

PMID: 39511139 PMC: 11544004. DOI: 10.1038/s41392-024-02005-w.

References

Pardoll D . Distinct mechanisms of tumor resistance to NK killing: of mice and men. Immunity. 2015; 42(4):605-6. PMC: 5598348. DOI: 10.1016/j.immuni.2015.04.007. View

Xiao G, Wang X, Sheng J, Lu S, Yu X, Wu J . Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. J Hematol Oncol. 2015; 8:13. PMC: 4342005. DOI: 10.1186/s13045-015-0110-z. View

Marcus A, Gowen B, Thompson T, Iannello A, Ardolino M, Deng W . Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014; 122:91-128. PMC: 4228931. DOI: 10.1016/B978-0-12-800267-4.00003-1. View

Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S . Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol. 2008; 180(11):7338-48. PMC: 3607742. DOI: 10.4049/jimmunol.180.11.7338. View

Finkernagel F, Reinartz S, Lieber S, Adhikary T, Wortmann A, Hoffmann N . The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget. 2016; 7(46):75339-75352. PMC: 5342745. DOI: 10.18632/oncotarget.12180. View

Bert N, Gasser S . Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol. 2014; 92(3):230-6. DOI: 10.1038/icb.2013.111. View

Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen J, Meissner W . Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2013; 134(1):32-42. PMC: 4232932. DOI: 10.1002/ijc.28335. View

Ullrich E, Koch J, Cerwenka A, Steinle A . New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013; 2(10):e26097. PMC: 3862635. DOI: 10.4161/onci.26097. View

Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N . Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol. 2008; 9(9):1065-73. DOI: 10.1038/ni.1642. View

10.

Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S . Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006; 12(9):1065-74. DOI: 10.1038/nm1452. View

11.

Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O . Characterization of tumor infiltrating natural killer cell subset. Oncotarget. 2015; 6(15):13835-43. PMC: 4537053. DOI: 10.18632/oncotarget.3453. View

12.

Lengyel E . Ovarian cancer development and metastasis. Am J Pathol. 2010; 177(3):1053-64. PMC: 2928939. DOI: 10.2353/ajpath.2010.100105. View

13.

Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S . Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v23-30. DOI: 10.1093/annonc/mdq244. View

14.

Lanier L . NKG2D Receptor and Its Ligands in Host Defense. Cancer Immunol Res. 2015; 3(6):575-82. PMC: 4457299. DOI: 10.1158/2326-6066.CIR-15-0098. View

15.

Salih H, Rammensee H, Steinle A . Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002; 169(8):4098-102. DOI: 10.4049/jimmunol.169.8.4098. View

16.

Ashiru O, Lopez-Cobo S, Fernandez-Messina L, Pontes-Quero S, Pandolfi R, Reyburn H . A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem J. 2013; 454(2):295-302. DOI: 10.1042/BJ20130194. View

17.

Eissmann P, Evans J, Mehrabi M, Rose E, Nedvetzki S, Davis D . Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol. 2010; 184(12):6901-9. DOI: 10.4049/jimmunol.0903985. View

18.

McGilvray R, Eagle R, Rolland P, Jafferji I, Trowsdale J, Durrant L . ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients. Int J Cancer. 2010; 127(6):1412-20. DOI: 10.1002/ijc.25156. View

19.

Lopez-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S . NKG2D signaling in cancer immunosurveillance. Int J Cancer. 2014; 136(8):1741-50. DOI: 10.1002/ijc.28775. View

20.

Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H . Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2008; 58(5):641-52. PMC: 11030581. DOI: 10.1007/s00262-008-0585-3. View